The Pharma Letter M&A roundup - July 2022

8 August 2022
mergers_acquisitions_2022_shutterstock_large

Big M&A rumors continue to swirl round the pharma world this summer, with talk of a Pfizer bid for Global Blood Therapeutics in the offing.

While the signs are that Pfizer is in advanced talks to complete the acquisition for around $5 billion, a rumored deal that has not yet happened has been Merck & Co's (NYSE: MRK) potential buy of US biotech Seagen (Nasdaq: SGEN).

In terms of what was announced in July, Anglo-Swedish pharma major AstraZeneca (LSE: AZN) was the only big pharma player to enter the M&A market, acquiring USA-based biotech TeneoTwo for $100 million upfront.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical